Optimer Presents Results From Fidaxomicin Phase III Study

Optimer Pharmaceuticals, Inc. announced that the results from its North American Phase 3 clinical study of fidaxomicin in patients with Clostridium difficile infection (CDI) were presented by clinical investigator Thomas J. Louie, M.D. for the first time in an oral presentation at the 19th annual European Congress of Clinical Microbiology and Infectious Diseases in Helsinki, Finland.
Baltimore Business Journal